Related Experiment Video
Updated: Sep 24, 2025
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
Blue-Light Therapy for Seasonal and Non-Seasonal Depression: A Systematic Review and Meta-Analysis of Randomized
André Do1, Victor W Li1, Samantha Huang1
1Department of Psychiatry, 8166University of British Columbia, Vancouver, Canada.
Objectives:
To determine the efficacy and safety of blue-light therapy in seasonal and non-seasonal major depressive disorder (MDD), by comparison to active and inactive control conditions.
Methods:
We searched Web of Science, EMBASE, Medline, PsycInfo, and Clinicaltrials.gov through January 17, 2022, for randomized controlled trials (RCTs) using search terms for blue/blue-enhanced, light therapy, and depression/seasonal affective disorder. Two independent reviewers extracted data. The primary outcome was the difference in endpoint scores on the Structured Interview Guide for the Hamilton Depression Rating Scale - Seasonal Affective Disorder (SIGH-SAD) or the Structured Interview Guide for the Hamilton Depression Rating Scale with Atypical Depression Supplement (SIGH-ADS) between blue light and comparison conditions. Secondary outcomes were response (≥ 50% improvement from baseline to endpoint on a depression scale) and remission rates (endpoint score in the remission range).
Results:
Of 582 articles retrieved, we included nine RCTs (n = 347 participants) assessing blue-light therapy. Seven studies had participants with seasonal MDD and two studies included participants with non-seasonal MDD. Four studies compared blue light to an inactive light condition (efficacy studies), and five studies compared it to an active condition (comparison studies). For the primary outcome, a meta-analysis with random-effects models found no evidence for the efficacy of blue-light conditions compared to inactive conditions (mean difference [MD] = 2.43; 95% confidence interval [CI], -1.28 to 6.14, P = 0.20); however, blue-light also showed no differences compared to active conditions (MD = -0.11; 95% CI, -2.38 to 2.16, P = 0.93). There were no significant differences in response and remission rates between blue-light conditions and inactive or active light conditions. Blue-light therapy was overall well-tolerated.
Conclusions:
The efficacy of blue-light therapy in the treatment of seasonal and non-seasonal MDD remains unproven. Future trials should be of longer duration, include larger sample sizes, and attempt to better standardize the parameters of light therapy.
Insights
Blue-light therapy shows no proven efficacy for treating major depressive disorder (MDD), whether seasonal or non-seasonal, compared to inactive or active controls. Further research with larger sample sizes and standardized parameters is needed.
Area of Science:
- Psychiatry and Behavioral Sciences
- Phototherapy Research
- Mood Disorder Treatment
Background:
- Major Depressive Disorder (MDD) encompasses seasonal and non-seasonal subtypes, often treated with light therapy.
- Blue-light therapy is a proposed intervention, but its efficacy requires rigorous evaluation against control conditions.
- Understanding the comparative effectiveness of blue-light therapy is crucial for evidence-based clinical practice.
Purpose of the Study:
- To assess the efficacy and safety of blue-light therapy for seasonal and non-seasonal Major Depressive Disorder (MDD).
- To compare blue-light therapy outcomes against both active and inactive control interventions.
- To evaluate the impact of blue-light therapy on depression symptom severity, response, and remission rates.
Main Methods:
- A systematic literature search was conducted across major databases (Web of Science, EMBASE, Medline, PsycInfo, Clinicaltrials.gov) up to January 2022.
- Included were nine randomized controlled trials (RCTs) involving 347 participants, assessing blue-light therapy for MDD.
- Primary outcome: difference in depression scale scores (SIGH-SAD/SIGH-ADS); Secondary outcomes: response and remission rates.
Main Results:
- Meta-analysis of four RCTs found no significant difference in efficacy between blue-light therapy and inactive control conditions (MD = 2.43, P = 0.20).
- Comparison with active control conditions also revealed no significant differences (MD = -0.11, P = 0.93).
- Response and remission rates did not differ significantly between blue-light and control groups; blue-light therapy was generally well-tolerated.
Conclusions:
- The current evidence does not support the efficacy of blue-light therapy for treating either seasonal or non-seasonal Major Depressive Disorder (MDD).
- Further high-quality research is recommended, focusing on longer trial durations, larger participant numbers, and standardized light therapy parameters.
- The therapeutic role of blue-light therapy in depression management remains unproven and requires additional investigation.
Related Concept Videos
01:30Electroconvulsive Therapy
01:05Long-term Depression
01:23Antidepressant Drugs: MAOIs and Other Agents
01:27Depressive Disorders: MDD and Dysthymia
01:18Depression: Overview
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs